RxDoctor Payments Data

Nathanial Grow, MD

Family Medicine · Petersburg, INNPI 1912900291

Payments from drug & device makers

$497in general payments, 2019–2025

Across 35 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$59
  • Lilly USA, LLC$56
  • AstraZeneca$51
  • Novo Nordisk$51
  • Takeda Pharmaceuticals U.S.A., Inc.$49
  • Amgen$35
  • plus $197 from 11 others

What the payments were for

  • Food & beverage$49099%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$497 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$39
Medicare patients
12
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$80,152
OzempicSemaglutide33$33,180
Bydureon BciseExenatide Microspheres22$30,632
JardianceEmpagliflozin39$21,235
MyrbetriqMirabegron44$15,649
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$14,102
FarxigaDapagliflozin Propanediol17$14,075
CreonLipase/Protease/Amylase17$12,587
RybelsusSemaglutide13$12,094
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$9,235
JanuviaSitagliptin Phosphate12$8,327
Repatha SureclickEvolocumab11$8,176
Lamotrigine ErLamotrigine37$7,610
Tresiba Flextouch U-100Insulin Degludec14$7,247
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen299$6,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$80,152194 claims
Novo NordiskOzempic, Rybelsus$51$45,27446 claims
Boehringer IngelheimJardiance$11$21,23539 claims
AstraZenecaFarxiga, Symbicort$51$18,54534 claims
AbbVieCreon$35$12,58717 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$49$6,26722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Petersburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →